Working... Menu

First in Human Study for RPH-104

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02667639
Recruitment Status : Unknown
Verified April 2017 by TRPHARM.
Recruitment status was:  Active, not recruiting
First Posted : January 29, 2016
Last Update Posted : April 21, 2017
Information provided by (Responsible Party):

Brief Summary:
The purpose of this fist in human study is to evaluate the safety and tolerability of RPH-104 in humans.

Condition or disease Intervention/treatment Phase
Healthy Biological: RPH-104 Other: Sodium chloride Sterile Injection 0.9% w/v Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: A Randomized, Double-blind, Placebo-controlled, Single-center, Phase I, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
Study Start Date : January 2016
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : September 2017

Arm Intervention/treatment
Active Comparator: Treatment
A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
Biological: RPH-104
Placebo Comparator: Placebo
A single 0.9% sodium chloride injection will be administered subcutaneously.
Other: Sodium chloride Sterile Injection 0.9% w/v

Primary Outcome Measures :
  1. Nature, frequency, severity and relationship to study drug of recorded adverse events [ Time Frame: Until 30 days after administration ]
    Assessment will be in accordance with current MedDRA

  2. Heart rate [ Time Frame: Until 30 days after administration ]
  3. Respiratory rate [ Time Frame: Until 30 days after administration ]
  4. Blood pressure [ Time Frame: Until 30 days after administration ]
  5. Oxygen saturation [ Time Frame: Until 30 days after administration ]
  6. Body temperature [ Time Frame: Until 30 days after administration ]
  7. Clinical laboratory tests [ Time Frame: Until 30 days after administration ]

Secondary Outcome Measures :
  1. RPH-104 - Maximum plasma concentration (Cmax) [ Time Frame: Day 1 ]
  2. RPH-104 - Area Under the Curve (AUC) [ Time Frame: Day 1 ]
  3. RPH-104 - Time to maximum concentration (Tmax) [ Time Frame: Day 1 ]
  4. RPH-104 - Elimination half-life (t1/2) [ Time Frame: Day 1 ]
  5. Levels of C-reactive protein (CRP) [ Time Frame: Until 30 days after administration ]
  6. Levels of serum amyloid A (SAA) [ Time Frame: Until 30 days after administration ]
  7. Levels of S100 calcium binding protein A8 (S100A8) [ Time Frame: Until 30 days after administration ]
  8. Interleukin-6 (IL-6) levels [ Time Frame: One month ]
  9. Interleukin-1alpha (IL-1a) levels [ Time Frame: Until 30 days after administration ]
  10. Interleukin-1beta (IL-1B) levels [ Time Frame: Until 30 days after administration ]
  11. Interleukin-1 receptor antagonist (IL-1RA) levels [ Time Frame: Until 30 days after administration ]
  12. Anti-RPH-104 antibody levels [ Time Frame: Until 30 days after administration ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects.
  • Male or female subjects between 18 and 35 years old (inclusive).
  • Subject who has normal body weight as determined by a body mass index (BMI) of between 18 kg/m² and 30 kg/m² (inclusive) and within a body weight of ≥50kg and ≤120kg.

Exclusion Criteria:

  • Subject who has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, dermatological, neurological, psychiatric, and hematological or immunological disorder(s), and/or any condition that could constitute a potential safety risk factor or could alter the absorption, distribution, metabolism or elimination of the study drugs.
  • Subject who has positive immunoglobulin-M (IgM) antibodies against Epstein Barr virus-viral capsid antigen (IgM-anti-EBV-VCA) and Cytomegalovirus (CMV).
  • Subject who has a positive Quantiferon TB-Gold (TB) test
  • Subject who is positive to Human Immunodeficiency Virus-1/2 antibody (HIV-1/2Ab).
  • Subject who has serum hepatitis, or is a carrier of the Hepatitis B surface antigen (HBsAg), or is Hepatitis C virus antibody (HCV-Ab) positive.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02667639

Layout table for location information
Izmir, Turkey
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Sibel Goksel, MD, PhD ARGEFAR

Layout table for additonal information
Responsible Party: TRPHARM Identifier: NCT02667639     History of Changes
Other Study ID Numbers: RPH104FIH01
First Posted: January 29, 2016    Key Record Dates
Last Update Posted: April 21, 2017
Last Verified: April 2017

Keywords provided by TRPHARM: